Scarica l'app Stockscreener
127.10
2.18%
-2.83
Dopo l'orario di chiusura:
127.00
-0.10
-0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
A Noteworthy Decision By Lee Heeson As Acquires $130K In Incyte Stock Options - Benzinga
James Michael Morrissey Expands Holdings With $54K Incyte Stock Options Acquisition - Benzinga
Incyte Q2 Earnings Call Highlights - Yahoo Finance
INCY Looks 18.3% Overvalued on GF Value™ as Growth Momentum Rema - GuruFocus
Earnings call transcript: Incyte Q2 2026 beats forecasts, lifts guidance - Investing.com
Incyte Corporation (INCY) Q2 2026 Earnings Call Transcript - AlphaStreet
Incyte lifts annual revenue forecast after settlement with CMS - Yahoo Finance
Incyte Corp reports results for the quarter ended June 30Earnings Summary - TradingView
Incyte Q2 Results: Adj. EPS $3.09 Beats Estimate, Sales Rise 37% - scanx.trade
INCY Looks 18.4% Overvalued on GF Value™ as of July 28, 2026 - GuruFocus
Incyte (INCY) Q2 Earnings and Revenues Top Estimates - Yahoo Finance Australia
INCY Looks 18.4% Overvalued on GF Value™ - GuruFocus
INCY Looks 18.4% Overvalued on GF Value™ as Growth Outlook Stren - GuruFocus
Is Incyte Corp (INCY) Worth the Current Valuation After Q2 Earni - GuruFocus
Incyte beats Q2 estimates but stock dips slightly on lowered guidance By Investing.com - Investing.com South Africa
Incyte (NASDAQ:INCY) Posts Better-Than-Expected Sales In Q2 CY2026 But Full-Year Sales Guidance Misses Expectations Significantly - Yahoo Finance
Incyte earnings beat by $1.10, revenue topped estimates - Investing.com
Incyte: Q2 Earnings Snapshot - 10TV
Incyte Revenue Rises 38 Percent to $1.67 Billion in Q2 - Quiver Quantitative
Incyte posts Q2 2026 revenue $1.67B, net income $586M; raises 2026 net sales outlook - TradingView
Incyte (NASDAQ: INCY) lifts 2026 sales outlook after strong Q2 results - Stock Titan
INCY|Incyte Corp|Price:118.880|Chg%:+1.210 - TradingKey
Form 4 Incyte Corporation For: 27 July By Investing.com - Investing.com South Africa
Incyte EVP Michael Morrissey Awarded Stock Options and Performance Shares in Equity Compensation Plan - Kalkine Media
Incyte Grants Heeson Lee Stock Options and Performance Shares Worth Notable Equity Compensation - Kalkine Media
Incyte (NASDAQ: INCY) awards EVP stock options, 8,999 performance shares - Stock Titan
Incyte Corp (INCY) awards options and performance shares to EVP - Stock Titan
INCY Looks 18.8% Overvalued on GF Value™ Heading into Q2 Earnings - GuruFocus
Incyte Corp (INCY) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Incyte Corp (INCY) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Incyte Corp (INCY) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Incyte Corporation stock hits 52-week high at 119.6 USD By Investing.com - Investing.com South Africa
Incyte Corporation stock hits 52-week high at 119.6 USD - Investing.com
Incyte earnings on deck: Can pipeline ease Jakafi concerns? By Investing.com - Investing.com South Africa
Incyte earnings on deck: Can pipeline ease Jakafi concerns? - Investing.com
INCYTE CORP (NASDAQ:INCY) Exhibits Perfect Technical Breakout Setup with Strong Ratings - ChartMill
What To Expect From Incyte’s (INCY) Q2 Earnings - Yahoo Finance
Incyte Corp (INCY) Balance Sheet - TradingKey
The week in pharma: action, reaction and insight – week to July 24, 2026 - The Pharma Letter
Incyte Corp (INCY) Income Statement - TradingKey
Incyte Gears Up to Report Q2 Earnings: Is a Beat Around the Corner? - Yahoo Finance
Incyte stock trades steady as Jakafi revenue supports 2024 outlook - AD HOC NEWS
INCYTE CORP (NASDAQ:INCY) Screens as a High Growth Momentum Stock with a Breakout Setup - ChartMill
INCY Maintained by JP Morgan -- Price Target Raised to $110 - GuruFocus
Incyte Corp (INCY) Valuation: PE, PB & Fair Value Analysis - TradingKey
INCY Maintained by Morgan Stanley -- Price Target Raised to $104 - GuruFocus
Incyte Corp (INCY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Incyte stock trades steadily as Jakafi revenue supports oncology pipeline - AD HOC NEWS
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
INCY Reiterated by HC Wainwright & Co. -- Price Target Maintained at $140 - GuruFocus
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine? - Yahoo Finance
Benchmark reiterates Halozyme stock Buy rating on Incyte deal - Investing.com
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
H.C. Wainwright reiterates Incyte stock rating on Halozyme deal - Investing.com
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte Corporation Officer Tray Thomas Awarded 2,834 RSUs and 4,079 Stock Options in July 2026 Equity Grant - Kalkine Media
Incyte Corp (INCY) grants RSUs and stock options to accounting chief - Stock Titan
Incyte Corp (INCY) grants RSUs, options as CMO Stein sells 1,877 shares - Stock Titan
Incyte Corp (INCY) awards RSUs, options and performance shares to CSO - Stock Titan
Equity grants to INCYTE CORP (INCY) R&D head and holdings - Stock Titan
Incyte (INCY) grants RSUs, options and performance shares to EVP - Stock Titan
Incyte Corp (INCY) awards RSUs, options and performance shares to EVP - Stock Titan
Incyte (NASDAQ: INCY) awards RSUs, options and performance shares to EVP - Stock Titan
INCYTE CORP (INCY) grants CEO stock options, RSUs and performance shares - Stock Titan
Halozyme enters license agreement with Incyte - The Pharma Letter
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations - Contract Pharma
Halozyme and Incyte announce global collaboration deal - grafa.com
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development - Yahoo Finance
Incyte adds Halozyme’s ENHANZE tech to first-in-class myeloproliferative neoplasm therapy - AllSci
Halozyme partners with Incyte on drug delivery technology - Investing.com
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - The AI Journal
1.32%
0.54%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):